Effect of standard (self-directed) training versus intensive training for Lilly/Alkermes human insulin inhalation powder delivery system on patient-reported outcomes and patient evaluation of the system

Diabetes Technology and Therapeutics

Volumn 9, Issue 1, 2007, Pages 89-98

  Hayes, Risa P ^a   Nakano, Masako ^a   Muchmore, Douglas ^a   Schmitke, Jennifer ^b  

^a ELI LILLY AND COMPANY   (United States)

^b ALKERMES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; EXPIRATORY FLOW RATE; FATIGUE; FEMALE; HUMAN; HYPOGLYCEMIA; INSPIRATORY FLOW RATE; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; PATIENT EDUCATION; PATIENT SATISFACTION; POWDER INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADMINISTRATION, INHALATION; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PATIENT EDUCATION; PATIENT SATISFACTION; RANDOM ALLOCATION; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 33847241849     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2006.0043     Document Type: Article

References (32)

1. Brown JB, Nichols GA: Slow response to loss of glycemic control in type 2 diabetes mellitus. Am J Manag Care 2003;9:213-217.
2. Brown JB, Nichols GA, Perry A: The burden of treatment failure in type 2 diabetes. Diabetes Care 2004;27:1535-1540.
3. Peyrot M, Mathews DR, Snoek FJ, Colagiuri R, Kleinebreil L, Rubin R, Ishii H, Lauritzen T, Geelhoed-Duijvestijn PHLM, Skovlund SE: An international study of psychological resistance to insulin use among persons with diabetes [abstract 249]. Diabetologia 2003;46(Suppl 2):A89.
4. Geelhoed-Duijvestijn PHLM, Peyrot M, Mathews DR, Rubin R, Kleinebreil L, Colaguiri R, Ishii H, Snoek FJ, Lauritzen T, Skovlund SE: Physician resistance to prescribing insulin: an international study [abstract 793]. Diabetologia 2003;46(Suppl 2):A274.
5. Cefalu WT: Concept, strategies, and feasibility of non-invasive insulin delivery. Diabetes Care 2004;27:239-246.
6. Riddle MC: The underuse of insulin therapy in North America. Diabetes Metab Res Rev 2002;18(Suppl): S42-S49.
7. American Diabetes Association: Insulin administration. Diabetes Care 2004;27(Suppl 1):S106-S109.
8. Rave KM, Nosek L, de la Pena A, Seger M, Ernest II CS, Heinemann L, Batycky RP, Muchmore DB: Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. Diabetes Care 2005;28:2400-2405.
9. Willke RJ, Burke LB, Erickson P: Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels. Control Clin Trials 2004;25:535-552.
10. Dickinson D, Wilkie P, Harris M: Taking medicines: concordance is not compliance. BMJ 1999;319:787.
11. Funnell MM, Anderson RM: Patient empowerment: a look back, a look ahead. Diabetes Educ 2003;29:454-464.
12. Rosenstock J, Nakano M, Sun B, de la Peña A, Suri A, Silverman BL, Muchmore DB: Comparison of standard (self-directed) versus intensive patient training for the human insulin inhalation powder (HIIP) delivery system in patients with type 2 diabetes: efficacy, safety, and training measures. Diabetes Technol Ther 2007;9:80-88.
13. Ware J: SF-36 Health Survey Manual & Interpretation Guide. Lincoln, RI: QualityMetric Inc., 2000.
14. Grootenhuis PA, Snoek FJ, Heine RJ, Bouter LM: Development of a type 2 diabetes symptom checklist: a measure of symptom severity. Diabet Med 1994;11:253-261.
15. Shen W, Kotsanos JG, Huster WJ, Mathias SD, Andrejasich CM, Patrick DL: Development and validation of the diabetes quality of life clinical trial questionnaire. Med Care 1999;37(Suppl 4):AS45-AS66.
16. Hayes R, Lenox S: Factor analysis and preliminary validation of Insulin Delivery System Questionnaire [abstract PDB35]. Value Health 2005;362.
17. Berelson B: Content analysis. In: Lindzey G, ed. Handbook of Social Psychology. Reading, MA: Addison-Wesley, 1954:488-518.
18. Wilson M, Moore MP, Lunt H: Treatment satisfaction after commencement of insulin in type 2 diabetes. Diabetes Res Clin Pract 2004;66:263-267.
19. Reza M, Taylor CD, Towse K, Ward JD, Hendra TJ: Insulin improves well-being for selected elderly type 2 diabetic subjects. Diabetes Res Clin Pract 2002;55:201-207.
20. Testa MA, Hayes JF, Turner RR, Hayes JF, Simonson DC: Quality of life improvements in type 2 diabetes when Exubera® is added after failure on metformin monotherapy: an international randomized phase 3 trial [abstract]. Diabetes 2004;53(Suppl 2):A437.
21. Hayes RP, Bowman L, Monahan PO, Marrero DG, McHorney CA: Understanding diabetes medications from the perspective of patients with type 2 diabetes. Prerequisite to medication concordance. Diabetes Educ 2006;32:404-414.
22. Stockl K, Vanderplas A, Ory C, Nicklasson L, Lyness W, Chang E: Evaluation of patient perceptions and psychological barriers to self-injection: the InnoLet insulin doser vs. standard vial/syringe [abstract]. Diabetes 2005;54(Suppl 1):A500.
23. Coscelli C, Lostia S, Lunetta M, Nosari I, Coronel GA: Safety, efficacy, acceptability of a pre-filled insulin pen in diabetic patients over 60 years old. Diabetes Res Clin Pract 1995;28:173-177.
24. Kadiri A, Chraibi A, Marouan F, Ababou MR, El Guermai N, Wadjinny A, Kerfati A, Douiri M, Bensouda JD, Belkhadir J, Arvanitis Y: Comparison of NovoPen 3 and syringes/vials in the acceptance of insulin therapy in NIDDM patients with secondary failure to oral hypoglycaemic agents. Diabetes Res Clin Pract 1998;41:15-23.
25. Shelmet J, Schwartz S, Cappleman J, Peterson G, Skovlund S, Lytzen L, Nicklasson L, Liang J, Lyness W; InnoLet Study Group: Preference and resource utilization in elderly patients: InnoLet versus vial/syringe. Diabetes Res Clin Pract 2004;63:27-35.
26. Dunbar JM, Madden PM, Gleeson DT, Fiad TM, McKenna TJ: Premixed insulin preparations in pen syringes maintain glycemic control and are preferred by patients. Diabetes Care 1994;17:874-878.
27. Kortykowski M, Bell D, Jacobsen C, Suwannasari R; FlexPen Study Team: A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 2003;25:2836-2848.
28. Niskanen L, Jensen LE, Rastam J, Nygaard-Pedersen L, Erichsen K, Vora JP: Randomized multinational, open-label, 2-period crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clin Ther 2004;26:531-540.
29. Royle P, Waugh N, McAuley L, McIntyre L, Thomas S: Inhaled insulin in diabetes mellitus. Cochrane Database Syst Rev 2004;(3):CD003890.
30. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Endocrinologic and Metabolic Drugs Advisory Committee. Thursday, September 8, 2005. http://www.fda.gov/ohrms/ dockets/ac/05/transcripts/2005-4169T1.pdf (accessed January 12, 2006).
31. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-986.
32. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2002;321:405-412.